Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies
June 29 2023 - 7:00AM
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq:
TCRT), a leading T-cell receptor (TCR) cell therapy company
advancing a clinical-stage pipeline of therapeutics for solid
tumors, today announced that the Company will present at the 2nd
Hawaii Global Summit on Thoracic Malignancies taking place June 27
– July 1, 2023.
Alaunos Director of Translational Sciences
Matthew Collinson-Pautz, Ph.D., will discuss the Company’s TCR-T
therapy in solid tumors targeting specific, cancer-driving
mutations currently being evaluated in a Phase 1/2 open-label,
dose-escalation trial at The University of Texas MD Anderson Cancer
Center.
Details of the presentation are as follows:
Title: Neoantigen Targeting TCR Engineered
Cellular Therapy for RAS-mutant TumorsSession
Title: Cellular TherapyPresentation Date and
Time: Friday, June 30, 11:27 a.m.
HSTPresenter: Dr. Collinson-Pautz
This summit brings together esteemed
translational and clinical researchers, as well as community
oncologists, to address the challenges and advancements in the
dynamic field of lung cancer and the evolution
of therapeutic approaches. For more information,
visit https://www.hawaiilung23.davaonc.com.
About the TCR-T Library Phase 1/2
TrialThe TCR-T Library Phase 1/2 trial is an open-label,
dose-escalation trial being conducted at MD Anderson. The trial is
actively enrolling patients with NSCLC, colorectal, endometrial,
pancreatic, ovarian and bile duct cancers that have a matching
human leukocyte antigen (HLA) whose tumors contain at least one of
the targeted driver mutations
in KRAS, TP53 and EGFR. Additional information
about the trial is available
at www.clinicaltrials.gov using the
identifier NCT05194735.
About Alaunos Therapeutics,
Inc.Alaunos Therapeutics is a leader in the science of
T-cell receptor (TCR) cell therapy working to revolutionize solid
cancer treatment and outcomes. The clinical-stage company’s TCR
T-cell therapy (TCR-T) is one of the most advanced TCR programs
targeting driver mutations in solid tumors with an ongoing Phase
1/2 trial of its TCR-T product candidates across six solid cancers.
Alaunos is powered by two proprietary platforms: its elegantly
efficient non-viral Sleeping Beauty cell engineering
platform; and its hunTR® discovery platform, which is
expanding its industry-leading library of TCRs against
high-frequency driver mutations. Alaunos is a part of an ongoing
collaboration with the National Cancer Institute (NCI), part of the
National Institutes of Health (NIH), working to advance the science
of TCR therapy. For more information,
visit www.alaunos.com.
Media Contact:Heather Anderson6 Degrees
PRhanderson@6degreespr.com
Investor Contact:Alex LoboStern Investor
RelationsAlex.lobo@sternir.com
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alaunos Therapeutics (NASDAQ:TCRT)
Historical Stock Chart
From Apr 2023 to Apr 2024